Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study

BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. METHODS AND RESULTS—The Bruneck study is a prospective population-based...

Full description

Saved in:
Bibliographic Details
Published inArteriosclerosis, thrombosis, and vascular biology Vol. 27; no. 8; pp. 1788 - 1795
Main Authors Kiechl, Stefan, Willeit, Johann, Mayr, Manuel, Viehweider, Brigitte, Oberhollenzer, Martin, Kronenberg, Florian, Wiedermann, Christian J., Oberthaler, Sabine, Xu, Qingbo, Witztum, Joseph L., Tsimikas, Sotirios
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Heart Association, Inc 01.08.2007
Hagerstown, MD Lippincott
Subjects
Online AccessGet full text

Cover

Loading…
Abstract BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. METHODS AND RESULTS—The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors. CONCLUSIONS—This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB.
AbstractList BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. METHODS AND RESULTS—The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors. CONCLUSIONS—This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB.
Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known.BACKGROUNDOxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known.The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors.METHODS AND RESULTSThe Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors.This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB.CONCLUSIONSThis study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB.
Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P=0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity (P=0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors. This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB.
Background— Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of OxPL/apoB levels to future cardiovascular events is not known. Methods and Results— The Bruneck study is a prospective population-based survey of 40- to 79-year-old men and women recruited in 1990. Plasma levels of OxPL/apoB and lipoprotein (a) [Lp(a)] were measured in 765 subjects in 1995 and incident cardiovascular disease (CVD), defined as cardiovascular death, myocardial infarction, stroke, and transient ischemic attack, was assessed from 1995 to 2005. During the follow-up period, 82 subjects developed CVD. In multivariable analysis, which included traditional risk factors, high sensitivity C-reactive protein (hsCRP), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, subjects in the highest tertile of OxPL/apoB had a significantly higher risk of cardiovascular events than those in the lowest tertile (hazard ratio[95% CI] 2.4[1.3 to 4.3], P =0.004). The strength of the association between OxPL/apoB and CVD risk was amplified with increasing Lp-PLA2 activity ( P =0.018 for interaction). Moreover, OxPL/apoB levels predicted future cardiovascular events beyond the information provided by the Framingham Risk Score (FRS). The effects of OxPL/apoB and Lp(a) were not independent of each other but they were independent of all other measured risk factors. Conclusions— This study demonstrates that OxPL/apoB levels predict 10-year CVD event rates independently of traditional risk factors, hsCRP, and FRS. Increasing Lp-PLA2 activity further amplifies the risk of CVD mediated by OxPL/apoB. Oxidized phospholipids (OxPL) detected by monoclonal antibody E06 (OxPL/apoB), lipoprotein(a), and Lp-PLA2 activity were measured in the Bruneck Study, where 82 of 765 subjects developed cardiovascular events over 10 years. OxPL/apoB and Lp(a) predicted 10-year cardiovascular events independently of traditional risk factors, hsCRP, and the Framingham risk score. Increasing Lp-PLA2 activity further amplified the risk mediated by OxPL/apoB and Lp(a).
Author Kiechl, Stefan
Tsimikas, Sotirios
Mayr, Manuel
Kronenberg, Florian
Viehweider, Brigitte
Oberthaler, Sabine
Wiedermann, Christian J.
Oberhollenzer, Martin
Xu, Qingbo
Willeit, Johann
Witztum, Joseph L.
AuthorAffiliation From the Department of Neurology (S.K., J.W.), the Division of General Internal Medicine (C.J.W., S.O., B.V., M.O.), and the Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology (F.K.), Medical University of Innsbruck, Austria; the Cardiovascular Division (Q.X., M.M.), King’s College London, University of London, UK; and the Department of Medicine (J.L.W., S.T.), University of California San Diego, La Jolla
AuthorAffiliation_xml – name: From the Department of Neurology (S.K., J.W.), the Division of General Internal Medicine (C.J.W., S.O., B.V., M.O.), and the Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology (F.K.), Medical University of Innsbruck, Austria; the Cardiovascular Division (Q.X., M.M.), King’s College London, University of London, UK; and the Department of Medicine (J.L.W., S.T.), University of California San Diego, La Jolla
Author_xml – sequence: 1
  givenname: Stefan
  surname: Kiechl
  fullname: Kiechl, Stefan
  organization: From the Department of Neurology (S.K., J.W.), the Division of General Internal Medicine (C.J.W., S.O., B.V., M.O.), and the Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology (F.K.), Medical University of Innsbruck, Austria; the Cardiovascular Division (Q.X., M.M.), King’s College London, University of London, UK; and the Department of Medicine (J.L.W., S.T.), University of California San Diego, La Jolla
– sequence: 2
  givenname: Johann
  surname: Willeit
  fullname: Willeit, Johann
– sequence: 3
  givenname: Manuel
  surname: Mayr
  fullname: Mayr, Manuel
– sequence: 4
  givenname: Brigitte
  surname: Viehweider
  fullname: Viehweider, Brigitte
– sequence: 5
  givenname: Martin
  surname: Oberhollenzer
  fullname: Oberhollenzer, Martin
– sequence: 6
  givenname: Florian
  surname: Kronenberg
  fullname: Kronenberg, Florian
– sequence: 7
  givenname: Christian
  surname: Wiedermann
  middlename: J.
  fullname: Wiedermann, Christian J.
– sequence: 8
  givenname: Sabine
  surname: Oberthaler
  fullname: Oberthaler, Sabine
– sequence: 9
  givenname: Qingbo
  surname: Xu
  fullname: Xu, Qingbo
– sequence: 10
  givenname: Joseph
  surname: Witztum
  middlename: L.
  fullname: Witztum, Joseph L.
– sequence: 11
  givenname: Sotirios
  surname: Tsimikas
  fullname: Tsimikas, Sotirios
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18940235$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17541022$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAURiNURH_gBVggb0AgNYPt2HHCLh1RWmmkqaAgsYoc50YxdeLUdlqGN-ItcTUDVVl0ZV_pnCvd7ztM9kY7QpK8JHhBSE7eV5ffTqqzakGwWBDGC8yfJAeEU5ayPMv34h-LMuU5o_vJofc_MMaMUvws2SeCM4IpPUh-r3_qVv-CFl301k-9NXrSrT9GKz3ZydkAenwr3z2Y08p7q7QMDyzpAVUUVSroGx02x0iOLSI4_Q7SoaV0rbY30qvZxHE9B2UH8B_QhYs-3DmAPoOfTfDo1NkBhR7QiZtHUFfoS5jbzfPkaSeNhxe79yj5evrxcnmWrtafzpfVKlWMUJ52nWIFybAoZNmQThY8w0Wel7QpccFIR0SDOe5KRUgjOImRtJwWESFMlpRDdpS82e6N117P4EM9aK_AGDmCnX0tsOAUFyKCr3bg3AzQ1pPTg3Sb-m-4EXi9A-Ld0nROjkr7e64oGaYZj1yx5VQMwzvoaqWDDNqOwUltaoLru77rXd9xFvW276jS_9R_2x-T8q10a00A56_MfAuu7kGa0D8m_gHPl78k
CODEN ATVBFA
CitedBy_id crossref_primary_10_2217_clp_11_72
crossref_primary_10_17116_kardio20158349_52
crossref_primary_10_1016_j_atherosclerosis_2024_117474
crossref_primary_10_1016_j_phrs_2017_02_001
crossref_primary_10_2217_clp_13_13
crossref_primary_10_1111_eci_13710
crossref_primary_10_1016_j_jacl_2022_10_004
crossref_primary_10_1016_j_cjca_2017_07_015
crossref_primary_10_2217_bmm_11_60
crossref_primary_10_1093_ije_dyp273
crossref_primary_10_1016_j_atherosclerosis_2009_09_077
crossref_primary_10_1194_jlr_M012526
crossref_primary_10_1007_s11033_010_0529_9
crossref_primary_10_1016_j_atherosclerosis_2011_09_019
crossref_primary_10_1080_10408363_2016_1188055
crossref_primary_10_1007_s11936_008_0047_4
crossref_primary_10_1016_j_amjcard_2008_04_015
crossref_primary_10_1016_j_jacc_2009_12_048
crossref_primary_10_1016_j_jacc_2013_09_042
crossref_primary_10_1016_j_amjcard_2008_04_018
crossref_primary_10_1016_j_ijcard_2013_01_182
crossref_primary_10_3389_fcvm_2024_1470364
crossref_primary_10_1016_j_jacl_2020_12_002
crossref_primary_10_1093_eurheartj_ehn502
crossref_primary_10_1016_j_amjcard_2009_09_052
crossref_primary_10_1016_j_jacl_2024_04_133
crossref_primary_10_1038_s41569_023_00937_4
crossref_primary_10_1093_hmg_ddw211
crossref_primary_10_1042_CS20080486
crossref_primary_10_1007_s12181_008_0065_1
crossref_primary_10_1016_j_jacl_2011_08_004
crossref_primary_10_1016_j_jicc_2014_08_004
crossref_primary_10_1016_j_plipres_2017_09_001
crossref_primary_10_1007_s10557_008_6133_8
crossref_primary_10_1007_s12170_010_0153_1
crossref_primary_10_1016_j_jacc_2016_11_042
crossref_primary_10_1016_j_amjcard_2008_04_014
crossref_primary_10_1016_j_jclinepi_2017_12_017
crossref_primary_10_1194_jlr_R024190
crossref_primary_10_1155_2012_480784
crossref_primary_10_1007_s11936_017_0549_z
crossref_primary_10_1016_j_jacc_2007_11_087
crossref_primary_10_1097_HCO_0b013e32832ac21a
crossref_primary_10_1007_s11883_008_0048_5
crossref_primary_10_1111_j_1460_9568_2009_06983_x
crossref_primary_10_1093_hmg_ddp424
crossref_primary_10_1016_j_jprot_2011_07_008
crossref_primary_10_1155_2011_418313
crossref_primary_10_1016_j_atherosclerosis_2012_06_020
crossref_primary_10_1194_jlr_P027235
crossref_primary_10_1007_s10157_013_0875_8
crossref_primary_10_1194_jlr_M040733
crossref_primary_10_1097_MOL_0b013e3282fe1d0e
crossref_primary_10_1016_j_atherosclerosis_2008_04_036
crossref_primary_10_1111_echo_70061
crossref_primary_10_1007_s11883_013_0360_6
crossref_primary_10_1194_jlr_R067314
crossref_primary_10_1016_j_neubiorev_2021_06_017
crossref_primary_10_1016_j_jacc_2007_11_079
crossref_primary_10_1042_BCJ20240037
crossref_primary_10_1016_j_freeradbiomed_2008_04_013
crossref_primary_10_1186_s12263_019_0658_2
crossref_primary_10_1016_j_jacc_2016_10_057
crossref_primary_10_1097_MOL_0b013e32832fa58d
crossref_primary_10_1016_j_pharmthera_2010_01_008
crossref_primary_10_3109_07853890_2011_582511
crossref_primary_10_2174_1568026623666230502140614
crossref_primary_10_1073_pnas_1800544115
crossref_primary_10_1161_ATVBAHA_115_305306
crossref_primary_10_18087_cardio_2019_12_n727
crossref_primary_10_1016_j_jacc_2013_08_1639
crossref_primary_10_1194_jlr_M060210
crossref_primary_10_1016_j_jacc_2012_08_979
crossref_primary_10_1007_s12263_011_0217_y
crossref_primary_10_1016_j_jacc_2008_02_066
crossref_primary_10_1194_jlr_M005769
crossref_primary_10_1080_07853890902769675
crossref_primary_10_1194_jlr_M800342_JLR200
crossref_primary_10_1186_s12944_017_0476_8
crossref_primary_10_1016_j_atherosclerosis_2009_12_036
crossref_primary_10_1016_j_jacc_2008_01_026
crossref_primary_10_1007_s10557_016_6648_3
crossref_primary_10_1155_2013_714653
crossref_primary_10_1016_j_jacc_2011_12_033
crossref_primary_10_3390_ijms24010170
crossref_primary_10_1016_j_jacc_2013_12_030
crossref_primary_10_1172_JCI63108
crossref_primary_10_1097_MOL_0b013e328308b622
crossref_primary_10_1016_j_coph_2013_02_005
crossref_primary_10_1016_j_jacc_2012_04_038
crossref_primary_10_1161_JAHA_120_015878
crossref_primary_10_1016_j_clinbiochem_2010_01_013
crossref_primary_10_1016_j_atherosclerosis_2022_10_002
crossref_primary_10_2217_clp_09_74
crossref_primary_10_2337_dc08_0349
crossref_primary_10_1007_s10557_015_6634_1
crossref_primary_10_1016_j_jacc_2007_11_051
crossref_primary_10_1097_MOL_0b013e3283598d81
crossref_primary_10_1021_acsmedchemlett_6b00281
crossref_primary_10_2217_14796678_5_2_159
crossref_primary_10_1016_j_atherosclerosis_2010_03_021
crossref_primary_10_3109_10408363_2014_992063
crossref_primary_10_1016_j_atherosclerosis_2022_04_001
crossref_primary_10_1016_j_numecd_2022_05_013
crossref_primary_10_3109_0886022X_2013_774680
crossref_primary_10_1007_s11883_010_0095_6
crossref_primary_10_1172_JCI58969
crossref_primary_10_3390_ijms24032237
crossref_primary_10_1194_jlr_P030890
crossref_primary_10_1016_j_clinbiochem_2012_03_031
crossref_primary_10_1016_j_jacc_2010_04_048
crossref_primary_10_1016_j_jacc_2023_02_051
crossref_primary_10_1007_s10557_008_6135_6
crossref_primary_10_1097_HCO_0000000000000300
crossref_primary_10_1097_MOL_0b013e328306f0cc
crossref_primary_10_1186_s12872_015_0001_9
crossref_primary_10_1016_j_pcad_2016_07_005
crossref_primary_10_1016_j_freeradbiomed_2012_08_004
crossref_primary_10_4155_bio_2019_0280
crossref_primary_10_3390_ijms25020736
crossref_primary_10_1039_C5FO00362H
crossref_primary_10_1007_s00431_023_04935_z
crossref_primary_10_1016_j_ijcard_2010_08_008
crossref_primary_10_1016_j_atherosclerosis_2008_10_040
crossref_primary_10_1016_j_jacl_2011_07_005
crossref_primary_10_1139_cjpp_2018_0490
crossref_primary_10_1161_JAHA_123_031825
crossref_primary_10_1186_1476_511X_13_59
crossref_primary_10_1038_s41569_018_0153_2
crossref_primary_10_1016_j_jacl_2012_01_004
crossref_primary_10_1089_ars_2009_2597
crossref_primary_10_1007_s12265_014_9590_4
crossref_primary_10_1194_jlr_M800174_JLR200
crossref_primary_10_3310_hta191000
crossref_primary_10_1161_ATVBAHA_113_301297
crossref_primary_10_5551_jat_6585
crossref_primary_10_1586_erc_12_32
crossref_primary_10_1016_j_jacc_2013_02_047
crossref_primary_10_1007_s12170_022_00698_8
crossref_primary_10_1016_j_freeradbiomed_2012_05_031
crossref_primary_10_1038_s41598_017_16464_5
crossref_primary_10_1016_j_jacc_2015_07_020
crossref_primary_10_1016_j_jacl_2016_01_005
crossref_primary_10_1258_cvd_2012_012011
crossref_primary_10_1186_1476_511X_10_170
crossref_primary_10_1016_j_thromres_2011_07_001
crossref_primary_10_1007_s11886_013_0417_8
crossref_primary_10_3390_ph3051360
crossref_primary_10_1007_s11883_012_0266_8
crossref_primary_10_1097_HCO_0b013e32832bcb22
crossref_primary_10_1016_j_amjcard_2008_02_006
crossref_primary_10_2217_bmm_2016_0096
crossref_primary_10_1007_s11239_016_1351_6
crossref_primary_10_4061_2011_156326
crossref_primary_10_1016_j_ijcard_2012_09_210
crossref_primary_10_1016_j_atherosclerosis_2008_08_045
crossref_primary_10_1002_biof_1890
crossref_primary_10_1007_s11883_008_0036_9
crossref_primary_10_1186_1476_511X_13_41
crossref_primary_10_1111_j_1365_2796_2012_02592_x
crossref_primary_10_1038_s41598_021_95141_0
crossref_primary_10_2217_17584299_4_1_41
crossref_primary_10_1186_1476_511X_11_4
crossref_primary_10_1253_circj_CJ_09_0924
crossref_primary_10_1016_j_cdtm_2017_02_008
crossref_primary_10_1007_s11892_019_1246_y
crossref_primary_10_1016_j_jacc_2009_02_041
crossref_primary_10_3390_molecules28030969
crossref_primary_10_1007_s11789_017_0090_3
crossref_primary_10_1194_jlr_R052258
crossref_primary_10_1194_jlr_E060947
crossref_primary_10_1016_j_jacc_2011_10_881
crossref_primary_10_1080_14737159_2017_1352472
crossref_primary_10_1194_jlr_R800074_JLR200
Cites_doi 10.1016/j.jacc.2005.02.058
10.1016/j.jacc.2006.03.024
10.1161/circ.102.10.1082
10.1111/j.1399-0004.1997.tb04342.x
10.1001/jama.1986.03380180102027
10.1016/0021-9150(96)05872-8
10.1016/S0092-8674(01)00238-0
10.1093/ajcn/36.5.936
10.1161/atvb.19.6.1484
10.1016/S0002-9149(96)00159-2
10.1016/j.cll.2006.06.003
10.1161/01.cir.0000141728.23033.b5
10.1161/circulationaha.104.529297
10.1016/j.jacc.2006.03.001
10.1016/S1567-5688(02)00045-4
10.1056/NEJMoa043175
10.1001/jama.296.11.1363
10.1056/NEJMoa001066
10.1016/S0735-1097(02)02769-9
10.1016/j.atherosclerosis.2004.01.029
10.1194/jlr.M600109-JLR200
10.1161/circ.100.11.1154
10.1016/j.atherosclerosis.2004.07.030
10.1194/jlr.R400001-JLR200
10.1016/S0009-8981(00)00216-3
10.1016/j.jacc.2005.12.047
10.1016/j.cll.2006.06.004
10.1161/01.cir.0000130844.01174.55
10.1056/NEJMra043430
10.1074/jbc.270.52.31151
10.1093/clinchem/36.1.20
ContentType Journal Article
Copyright 2007 American Heart Association, Inc.
2007 INIST-CNRS
Copyright_xml – notice: 2007 American Heart Association, Inc.
– notice: 2007 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/ATVBAHA.107.145805
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4636
EndPage 1795
ExternalDocumentID 17541022
18940235
10_1161_ATVBAHA_107_145805
10.1161/ATVBAHA.107.145805
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: HL56989
GroupedDBID ---
.3C
.55
.GJ
.Z2
01R
0R~
1J1
23N
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABZAD
ABZZY
ACCJW
ACDDN
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACPRK
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFBFQ
AFDTB
AFFNX
AFUWQ
AGINI
AHJKT
AHMBA
AHOMT
AHQNM
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BOYCO
BQLVK
BS7
C1A
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FRP
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB2
OCUKA
ODA
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
PZZ
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
ZGI
ZZMQN
AAYXX
ADGHP
CITATION
IQODW
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OK1
OLW
RHF
7X8
ID FETCH-LOGICAL-c4125-ffc4813078a9b1fa853086692b90841f17b050f9c11b751004d52808614a925e3
ISSN 1079-5642
1524-4636
IngestDate Fri Jul 11 16:58:53 EDT 2025
Wed Feb 05 09:37:54 EST 2025
Mon Jul 21 09:14:58 EDT 2025
Tue Jul 01 02:21:24 EDT 2025
Thu Apr 24 23:01:48 EDT 2025
Fri May 16 03:46:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Prognosis
Enzyme
Phospholipid
Cardiovascular disease
Esterases
Phospholipase A
lipoprotein-associated phospholipase A2
Lipoprotein a
Carboxylic ester hydrolases
lipoprotein (a)
Vascular disease
Atherosclerosis
Hydrolases
Oxidation
oxidized phospholipids
lipoproteins
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4125-ffc4813078a9b1fa853086692b90841f17b050f9c11b751004d52808614a925e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17541022
PQID 70752087
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_70752087
pubmed_primary_17541022
pascalfrancis_primary_18940235
crossref_citationtrail_10_1161_ATVBAHA_107_145805
crossref_primary_10_1161_ATVBAHA_107_145805
wolterskluwer_health_10_1161_ATVBAHA_107_145805
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-August
PublicationDateYYYYMMDD 2007-08-01
PublicationDate_xml – month: 08
  year: 2007
  text: 2007-August
PublicationDecade 2000
PublicationPlace Philadelphia, PA
Hagerstown, MD
PublicationPlace_xml – name: Philadelphia, PA
– name: Hagerstown, MD
– name: United States
PublicationTitle Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate Arterioscler Thromb Vasc Biol
PublicationYear 2007
Publisher American Heart Association, Inc
Lippincott
Publisher_xml – name: American Heart Association, Inc
– name: Lippincott
References e_1_3_3_17_2
e_1_3_3_16_2
e_1_3_3_19_2
e_1_3_3_18_2
e_1_3_3_13_2
(e_1_3_3_10_2) 2004; 25
e_1_3_3_12_2
e_1_3_3_15_2
e_1_3_3_14_2
e_1_3_3_32_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_31_2
e_1_3_3_6_2
e_1_3_3_5_2
e_1_3_3_8_2
e_1_3_3_7_2
e_1_3_3_28_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_24_2
e_1_3_3_23_2
e_1_3_3_26_2
e_1_3_3_25_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_1_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_3_2
e_1_3_3_21_2
References_xml – ident: e_1_3_3_3_2
  doi: 10.1016/j.jacc.2005.02.058
– volume: 25
  start-page: e71.
  year: 2004
  ident: e_1_3_3_10_2
  publication-title: Arterioscler Thromb Vasc Biol
– ident: e_1_3_3_13_2
  doi: 10.1016/j.jacc.2006.03.024
– ident: e_1_3_3_20_2
  doi: 10.1161/circ.102.10.1082
– ident: e_1_3_3_26_2
  doi: 10.1111/j.1399-0004.1997.tb04342.x
– ident: e_1_3_3_22_2
  doi: 10.1001/jama.1986.03380180102027
– ident: e_1_3_3_30_2
  doi: 10.1016/0021-9150(96)05872-8
– ident: e_1_3_3_1_2
  doi: 10.1016/S0092-8674(01)00238-0
– ident: e_1_3_3_32_2
  doi: 10.1093/ajcn/36.5.936
– ident: e_1_3_3_12_2
  doi: 10.1161/atvb.19.6.1484
– ident: e_1_3_3_23_2
  doi: 10.1016/S0002-9149(96)00159-2
– ident: e_1_3_3_27_2
  doi: 10.1016/j.cll.2006.06.003
– ident: e_1_3_3_9_2
  doi: 10.1161/01.cir.0000141728.23033.b5
– ident: e_1_3_3_17_2
  doi: 10.1161/circulationaha.104.529297
– ident: e_1_3_3_6_2
  doi: 10.1016/j.jacc.2006.03.001
– ident: e_1_3_3_28_2
  doi: 10.1016/S1567-5688(02)00045-4
– ident: e_1_3_3_5_2
  doi: 10.1056/NEJMoa043175
– ident: e_1_3_3_25_2
  doi: 10.1001/jama.296.11.1363
– ident: e_1_3_3_19_2
  doi: 10.1056/NEJMoa001066
– ident: e_1_3_3_7_2
  doi: 10.1016/S0735-1097(02)02769-9
– ident: e_1_3_3_16_2
  doi: 10.1016/j.atherosclerosis.2004.01.029
– ident: e_1_3_3_18_2
  doi: 10.1194/jlr.M600109-JLR200
– ident: e_1_3_3_24_2
  doi: 10.1161/circ.100.11.1154
– ident: e_1_3_3_31_2
  doi: 10.1016/j.atherosclerosis.2004.07.030
– ident: e_1_3_3_4_2
  doi: 10.1194/jlr.R400001-JLR200
– ident: e_1_3_3_14_2
  doi: 10.1016/S0009-8981(00)00216-3
– ident: e_1_3_3_11_2
  doi: 10.1016/j.jacc.2005.12.047
– ident: e_1_3_3_15_2
  doi: 10.1016/j.cll.2006.06.004
– ident: e_1_3_3_8_2
  doi: 10.1161/01.cir.0000130844.01174.55
– ident: e_1_3_3_2_2
  doi: 10.1056/NEJMra043430
– ident: e_1_3_3_29_2
  doi: 10.1074/jbc.270.52.31151
– ident: e_1_3_3_21_2
  doi: 10.1093/clinchem/36.1.20
SSID ssj0004220
Score 2.3590758
Snippet BACKGROUND—Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The...
Background— Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The...
Oxidized phospholipids (OxPL) circulate on apolipoprotein B-100 particles (OxPL/apoB), and primarily on Lp(a) lipoprotein (a) [Lp(a)]. The relationship of...
SourceID proquest
pubmed
pascalfrancis
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1788
SubjectTerms 1-Alkyl-2-acetylglycerophosphocholine Esterase - blood
1-Alkyl-2-acetylglycerophosphocholine Esterase - metabolism
Age Factors
Aged
Apolipoprotein B-100 - blood
Apolipoprotein B-100 - metabolism
Atherosclerosis (general aspects, experimental research)
Atherosclerosis - diagnosis
Atherosclerosis - epidemiology
Biological and medical sciences
Biomarkers - blood
Blood and lymphatic vessels
Cardiology. Vascular system
Coronary Artery Disease - enzymology
Coronary Artery Disease - epidemiology
Coronary Artery Disease - physiopathology
Disease Progression
Diseases of the cardiovascular system
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Fundamental and applied biological sciences. Psychology
General aspects
Humans
Male
Medical sciences
Middle Aged
Phospholipases A2
Phospholipids - blood
Phospholipids - metabolism
Population Surveillance
Predictive Value of Tests
Probability
Prognosis
Proportional Hazards Models
Prospective Studies
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Risk Factors
Sensitivity and Specificity
Severity of Illness Index
Sex Factors
Survival Analysis
Vertebrates: cardiovascular system
Title Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study
URI https://www.ncbi.nlm.nih.gov/pubmed/17541022
https://www.proquest.com/docview/70752087
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIiEkhLgJR9kHHkCtW6-ztnd5M1VQSikImqL2yfK1Imqwo8bm6E_iL_LCjL2-SlSOh1i25c3ams87h2e-IeQpH0UKZJsY-EkIQzeWIdXIMWI3AI0UBSouief33zqTQ_76yD4aDH52spaKPNyKzlbWlfyPVOEcyBWrZP9Bss2fwgnYB_nCFiQM27-S8btvs3h2Bibj4lO2hN98tpjFpWBgLyspGNDvF2AgynNnjUDLpTc6QJoSqyTY-KLbBWBgHRbR70j4E_WTV7Mih6fCuO3Iw4qDumpzA1z4Yp4v29qV8LRIk-ikQ2bbEN8iV3S2hAeD8RXfAXZu-BzWRzh_M6OmjGq0xO54Z_JGJ6upFucYohjvTnWqcZC2ycYHsFbveWW64kGWz3DqBnLe8YeqeiktdB1BHQ1xm1w8HQ1pWC06a7rpSsN2eG_RrwgJNLhFZwVnbtVmUFsDsF7ZqzWNg5rGm3586U28LYZxOm4L0271ap1LcE7dNkmQTEiObEOXyGULfBxsv7H3vkN1b1kVlYa--7riy2Hbv8_as6quAVrgBVdVZ5ZVrhNc8zXDbIzlSVmM0TGppjfIde0LUa8C9k0ySNJb5Mq-zva4TX7U-KY9fG_SDo6fBc97xx1c0x6uqWfRGtebFFBFNappH9W0RjV9QTuYphrTFDFNAdNUY5qWmL5DDl-NpzsTQ_cWMSIONr2hVMQF2G-uCGTIVABWKzj3jrRCaQrOFHND0zaVjBgLXRtpFWPbEnAJ44G07GR0l6ylWZrcJzQWI8USAX6ECjCeIIV0uIQJgkg4UvEhYbVs_EgT72P_l7lfOuAO87U84dj1K3kOyUYzZlHRzlx49XpP5O0QDbEheVJjwAf1gd8EgzTJiqXvgstgmcIdknsVNNqxrs0xHDQk2z2s-FWB9gW38-BPt_OQXG3f3UdkLT8tksdg2-fhevkO_AJLCf0R
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oxidized+phospholipids%2C+lipoprotein%28a%29%2C+lipoprotein-associated+phospholipase+A2+activity%2C+and+10-year+cardiovascular+outcomes+%3A+Prospective+results+from+the+bruneck+study&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=KIECHL%2C+Stefan&rft.au=WILLEIT%2C+Johann&rft.au=TSIMIKAS%2C+Sotirios&rft.au=MAYR%2C+Manuel&rft.date=2007-08-01&rft.pub=Lippincott&rft.issn=1079-5642&rft.volume=27&rft.issue=8&rft.spage=1788&rft.epage=1795&rft_id=info:doi/10.1161%2FATVBAHA.107.145805&rft.externalDBID=n%2Fa&rft.externalDocID=18940235
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon